Our proprietary PCR-based in vitro molecular diagnostic assays for detection of somatic mutations in solid and liquid biopsies. Based on PentaBase’s novel and selective INA® technologies Microsight®, PlentiPlex™ and SensiScreen® assays provide complementary diagnostics and monitoring of clinically relevant somatic mutations in BRAF, EGFR, KIT, KRAS, NRAS, MSI, MYD88 and PIK3CA genes.
Our proprietary real-time PCR-based SensiScreen® and PlentiPlex™ MYD88 L265P assays for somatic mutation detection in cancer patients combine ultra-high sensitivity with multiplexing capabilities, speed, ease-of-use and little hands-on-time. Complementary diagnostics and monitoring of key cancer genes in solid and liquid biopsies.
MicroSight® and PlentiPlex™ MSI assays are intended for evaluation of impaired DNA mismatch repair (MMR) affecting prognosis and selection of treatment in cancer patients. The MicroSight® MSI assays enables fast and easy evaluation of MSI status by real-time PCR and high resolution melt analysis whereas the PlentiPlex™ MSI assays offer length analysis of five multiplexed microsatellite loci using genetic analyzers.
Mastocytosis is a disorder characterized by growth and accumulation of neoplastic mast cells within various organs and most commonly the skin. PlentiPlex™ Mastocytosis assay is designed to identify the presence of the KIT D816V mutation in mast cells to assist the diagnosis of mastocytosis.